$82 billion pharma giant Bristol-Myers Squibb just suffered a major setback in its hunt for a lung cancer treatment, but the drugmaker isn’t backing away from its controversial strategy (BMY)
|01/24/2019||Posted by BusinessMediaguide.Com under General World News||
- Bristol-Myers Squibb has been trying to prove that its existing cancer drugs can help patients with a common form of lung cancer — but the company just announced that it voluntarily withdrew its application to sell the drugs for this condition.
- The development is a major setback that could throw the $82 billion drugmaker’s cancer strategy into question.
- Bristol-Myers executives said on a Thursday call that they are still sticking with the approach, and emphasized the promise of key cancer drugs Opdivo and Yervoy.
Lung cancer is the most deadly kind of cancer in the U.S., and a crucial market for read more >>>